Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aaron M. Chapman"'
Autor:
Laura Petersen, Michael R. Irwin, Matt Hogan, Patricia A. Ganz, Elizabeth C. Breen, Robert H. Schiestl, Aaron M. Chapman, Stephanie Esquivel, Sam Ramos-Perlberg, Judith E. Carroll, Julienne E. Bower, Zorica Scuric
Publikováno v:
NPJ breast cancer, vol 3, iss 1
NPJ Breast Cancer
npj Breast Cancer, Vol 3, Iss 1, Pp 1-7 (2017)
NPJ Breast Cancer
npj Breast Cancer, Vol 3, Iss 1, Pp 1-7 (2017)
Radiation and chemotherapy are effective treatments for cancer, but are also toxic to healthy cells. Little is known about whether prior exposure to these treatments is related to markers of cellular aging years later in breast cancer survivors. We e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3910197184fe334ab219ba37cdc8ce67
https://escholarship.org/uc/item/6176c896
https://escholarship.org/uc/item/6176c896
Publikováno v:
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 769:100-107
Asthma is a common heterogeneous disease with both genetic and environmental factors that affects millions of individuals worldwide. Activated type 2 helper T cells secrete a panel of cytokines, including IL-13, a central immune regulator of many of
Publikováno v:
Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis. 749:58-65
Cigarette smoke causes direct oxidative DNA damage as well as indirect damage through inflammation. Epidemiological studies show a strong relationship between secondhand smoke and cancer; however, the mechanisms of secondhand smoke-induced cancer are
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 102
Lung cancer is the leading cause of cancer-related mortality. While the majority of lung cancers are associated with tobacco smoke, approximately 10-15% of U.S. lung cancers occur in never smokers. Evidence suggests that lung cancer in never smokers
Autor:
Stavroula Baritaki, Kam C. Yeung, James R. Berenson, Demetrios A. Spandidos, Aaron M. Chapman, Katherine Wu, Michael A. Palladino, Benjamin Bonavida
Publikováno v:
Blood. 112:2611-2611
A subset of patients with B cell malignancies does not respond to conventional current cytotoxic therapies. Novel immunotherapeutic approaches have been considered such as TRAIL and agonist DR4/DR5 mAbs that are currently in phase I/II clinical trial